Last reviewed · How we verify
CMV Specific Cytotoxic T Lymphocytes
At a glance
| Generic name | CMV Specific Cytotoxic T Lymphocytes |
|---|---|
| Sponsor | Milton S. Hershey Medical Center |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Constipation
- Weight loss
- Memory impairment
- Anorexia
- Anxiety
- Cognitive Disturbance
- Depression
- Malaise
- Seizure
- Urinary tract infection
- Concentration impairment
- Insomnia
Key clinical trials
- Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection (PHASE2)
- Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT (EARLY_PHASE1)
- TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT. (PHASE1)
- Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) (PHASE2)
- TETRAVI Expanded Access Program
- Allogeneic Virus-specific T Cell Lines (VSTs) (PHASE1)
- Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant (PHASE2, PHASE3)
- Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: